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Esophageal squamous cell carcinoma (ESCC) is one of the most common malig-
nant tumors. Although improvement in both surgical techniques and neoadju-
vant chemotherapy has been achieved, the 5-year survival rate of locally
advanced tumors was, at best, still 55%. Therefore, elucidation of mechanisms of
the malignancy is eagerly awaited. Epithelial-mesenchymal transition (EMT) by
transforming growth factor-b (TGF-b) has been reported to have critical biological
roles for cancer cell stemness, whereas little is known about it in ESCC. In the
current study, a transcriptional factor SIX1 was found to be aberrantly expressed
in ESCCs. SIX1 cDNA transfection induced overexpression of transforming growth
factors (TGFB1 and TGFB2) and its receptor (TGFBR2). Cell invasion was reduced
by SIX1 knockdown and was increased in stable SIX1-transfectants. Furthermore,
the SIX1-transfectants highly expressed tumor basal cell markers such as NGFR,
SOX2, ALDH1A1, and PDPN. Although mock-transfectants had only a 20% PDPN-
high population, SIX1-transfectants had 60–70%. In two sets of 42 and 85 ESCC
patients receiving surgery alone or neoadjuvant chemoradiotherapy followed by
surgery, the cases with high SIX1 mRNA and protein expression level significantly
showed a poor prognosis compared with those with low levels. These SIX1 high
cases also expressed the above basal cell markers, but suppressed the differentia-
tion markers. Finally, TGF-b signaling blockade suppressed ESCC cell growth in
association with the reduction of PDPN-positive tumor basal cell population. The
present results suggest that SIX1 accelerates self-renewal of tumor basal cells,
resulting in a poor prognosis for ESCC patients.
E sophageal squamous cell carcinoma (ESCC) is one of themost common malignant tumors in Eastern Asia with
extremely poor prognosis due to late presentation and rapid
progression.(1) Neoadjuvant chemoradiotherapy (CRT) fol-
lowed by surgery is the standard therapy in Western countries,
whereas neoadjuvant chemotherapy followed by surgery and
definitive CRT are the standard therapies in Japan.(2) Although
improvement in both surgical techniques and neoadjuvant
chemotherapy has been achieved, the 5-year survival rate of
locally advanced tumors was, at best, still 55%.(3) Local recur-
rence, lymph node metastasis, and distant metastasis are major
causes of such a poor prognosis. Therefore, elucidation of this
mechanism is eagerly awaited.
Epithelial-mesenchymal transition (EMT), well-known to be
critical to a defining structural feature of organ development,
is involved in disease progression, including that of cancer.(4)
Its induction can cause enhanced cellular motility and inva-
siveness which is essential for metastasis, and often leads to
the acquisition of stem cell properties.(5) Stemness properties
are characterized by apoptosis resistance, transient quiescence,
and self-renewal capacities, all of which cause a poor progno-
sis through metastasis and drug resistance. Despite its defini-
tive biological role for cancer progression, little is known
about the cancer stem cells of ESCC compared to other solid
tumor stem cells.(6)
Since the first report by Feinberg et al., aberrant DNA
hypometyhlations have been observed in several types of can-
cer and have also been reported to be associated with tumori-
genesis and metastasis.(7) We investigated such aberrantly
expressed genes in ESCC by comparative microarray profiling
between normal and tumor tissues.(8) Consequently, we found
some aberrantly expressed genes, including SIX1. Among SIX
homeodomain transcription factors, SIX1, SIX2 and SIX4,
have an important role in the expansion of progenitor cell pop-
ulations during early embryogenesis,(9) and are known to be
essential for the development of numerous organs.(10–12)
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Particularly, SIX1 has reported to be overexpressed and associ-
ated with poor prognosis in various human cancers.(13–18) In
breast cancer, SIX1 induces EMT- and stem cell-like pheno-
types through the upregulation of transforming growth factor b
(TGF-b) signaling.(18–20) In ESCC, we revealed that SIX1 also
induces EMT, inhibits cell differentiation, and promotes self-
renewal of cancer stem cells via TGF-b signaling, and that its
inhibition causes the reduction of stem cell population and
induction of cell death. Therefore, the SIX1-regulated TGF-b
signaling pathway has a potential to be a therapeutic target in
ESCC.
Materials and Methods
Tissue samples of ESCC and normal esophagus. Both esopha-
geal cancer tissues and their matched noncancerous tissues
were obtained with written informed consent from locally
advanced ESCC patients who underwent esophagectomy at the
National Cancer Center Hospital (Tokyo, Japan) and Hir-
oshima University Hospital (Hiroshima, Japan), and biopsy
samples of locally advanced ESCC before treatment were pro-
vided by the National Cancer Center Hospital East (Kashiwa,
Japan) after obtaining written informed consent from each
patient and approval by the institutional review boards.
Cell culture. All ESCC-derived cell lines were cultured in
RPMI-1640 (Wako Pure Chemical Industries, Osaka, Japan)
supplemented with 10% fetal bovine serum, penicillin-strepto-
mycin at 37°C, with 5% CO2 in 95% humidified air.
Laser-captured micro-dissection (LCM). The human esophagus
was embedded in TissueTek OCT medium (Sakura Finetek
Europe B.V., Alphen aan den Rijn, Netherlands) and snap-fro-
zen in liquid nitrogen. The cryostat sections (8 lm) were
laser-microdissected with a PixCell II LCM system (Arcturus
Engineering, Mountain View, CA, USA).
RNA extraction and microarray analysis. For total RNA isola-
tion, surgical specimens and esophageal epithelial cells of mice
were lysed by ISOGEN lysis buffer (Nippon Gene, Toyama,
Japan), extracted with chloroform, and precipitated with a
glycogen carrier in isopropanol. The mRNA was amplified by
an efficient method of high-fidelity mRNA amplification
developed by us, called TALPAT (T7RNA polymerase pro-
moter-attached, adaptor ligation mediated, and PCR amplifica-
tion followed by in vitro T7-transcription).
Reverse Transcription-PCR and quantitative real-time PCR. Ten
micrograms of cRNA from 1 to 5 lg total RNA was prepared
from the esophageal cancer cell lines and the surgical speci-
mens of esophageal cancer by T7 transcription-mediated RNA
amplification. Single stranded cDNAs were synthesized from
5 lg cRNA by use of First-strand synthesis kit (Amersham
Biosciences, Piscataway, NJ, USA) with random hexamers.
We performed RT-PCR by Accuprime PCR system (Invitro-
gen, Carlsbad, CA, USA). The thermal profile consisted of an
initial denaturation at 95°C for 5 min followed by repetitions
at 95°C for 1 min, 56°C for 1 min, and 72°C for 1 min, with
a final extension step at 72°C for 10 min. All of the genes
from 50 ng of the cDNA template were amplified with multi-
ple cycle numbers (20–50 cycles) to determine the appropriate
conditions for obtaining semiquantitative differences in gene
expression levels. Quantitative real-time PCR was performed
by a Bio-Rad iCycler with iQ Syber Green Supermix (Bio-
Rad, Hercules, CA, USA) as directed by the manufacturer.
The value of 1/2N (N: the number of PCR cycles correspond-
ing to the onset of the linear amplification of each gene pro-
duct) was calculated as a relative mRNA expression level of
each gene normalized to ACTB. Primers used for the study are
listed in Supplementary Table S1.
Plasmid construct and transfection. The pCMV6-XL5 con-
taining SIX1 cDNA was purchased from OriGene Technologies
(Rockville, MD, USA) and integrated into pcDNA3.1 vector
(Invitrogen). 2 9 104 cells were inoculated, and then trans-
fected with either pcDNA3.1-SIX1, or no insert of pcDNA3.1-
mock using Lipofectamine 2000 reagents according to the
manufacturer’s protocol (Invitrogen). The cells were selected
with 0.5 mg/mL G418 (Invitrogen) from 2 days post-transfec-
tion, and simultaneously harvested at 2 days after transfection
for RT-PCR analysis. Cells were also subjected to limiting
dilution in a 96-well plate for obtaining colonies. SIX1 mRNA
expression levels of the clones were examined by quantitative
RT-PCR.
Immunohistochemical analysis. Specimens fixed in formalin
and embedded in paraffin were cut into 4-lm sections, subse-
quently dewaxed, and dehydrated. Sections were blocked for
DAKO protein block (DAKO, Carpinteria, CA, USA), and
stained with primary antibodies against Six1 (1:100, Atlas anti-
bodies, Stockholm, Sweden), and PDPN (1:50, Acris Antibod-
ies GmbH, Herford, Germany) at 4°C overnight, followed by
incubation with EnVsion + Dual Link System-HRP (DAKO).
Subsequently, these sections were exposed by DAB for 5 min.
The slides were counterstained with hematoxylin and then
mounted.
Immunofluorescence staining. Cells were cultured on glass
chamber slides, and then fixed with 4% paraformaldehyde, per-
meabilized with 20°C methanol and 0.5% Triton X-100/PBS,
and blocked with 0.1M NH4Cl, 10% fetal bovine serum and
2% bovine serum albmine in phosphate -buffered saline (PBS).
Cells were incubated with primary antibody for PDPN (1:50,
Acris Antibodies GmbH), and then incubated with Alexa488-
conjugated anti-mouse IgG antibody (1:800, Invitrogen) and
stained with DAPI.
siRNA transfection. Purchased siRNA (ID: s227324, Ambion,
Austin, TX, USA) were transfected to ESCC cells using Dhar-
maFECT (Thermo Fisher Scientific, Waltham, MA, USA) fol-
lowing the procedure recommended by the manufacturer.
Quantitative RT-PCR and Matrigel invasion assay were carried
out after siRNA treatment of ESCC cells.
Matrigel invasion assay. Invasion abilities of ESCC cells
in vitro were measured by BD BioCoat Matrigel Invasion
Chamber (BD Biosciences, San Jose, CA, USA) according to
the manufacturer’s protocol. The cells were trypsinized and
transferred into wells at 24 h after siRNA transfection. After
incubation for 24 h, the cells that passed through the filter into
the lower wells were fixed, stained, and counted.
Flow cytometry analysis. Cells were harvested, and incubated
with anti-PDPN antibody (1:100, Abcam, Cambridge, UK) or
isotype control mouse IgG1 for 30 min on ice followed by
PBS washing. Anti-mouse IgG-Alexa488 (1:800; Invitrogen)
was used as a secondary antibody. Dead cells were labeled
with propidium iodide and were excluded from the analysis.
Flow cytometry analysis was performed using FACSCalibur
(BD Biosciences).
Western blot. Cells were lysed in Laemmli Sample buffer
(Bio-Rad, Hercules, CA, USA) containing DTT and 1% pro-
tease inhibitor cocktail. Nuclear extracts at 24 h after TGF-b
(R&D Systems, Minneapolis, MN, USA) treatment or at 48 h
after TGF-b receptor inhibitor (A-83-01, Wako, Tokyo, Japan)
treatment were prepared by using NE-PER Nuclear and Cyto-
plasmic Extraction Reagents (Thermo Fisher Scientific). The
samples were separated using 12% SDS-PAGE. Proteins were
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transferred to polyvinylidene fluoride (PVDF) membrane and
blocked with 5% membrane blocking agent (GE Healthcare,
Buckinghamshire, UK) in PBS, and probed with anti-SIX1
antibody (1:250, Acris Antibodies GmbH, Herford, Germany)
or anti-phospho-smad2/3 antibody (1:500, Cell Signaling Tech-
nology, Danver, MA, USA) at 4°C overnight, anti-a tubulin
antibody (1:1000; Santa Cruz, Dallas, Tx, USA) at room tem-
perature for 1 h or anti-b actin antibody (1:2000; Cell Signal-
ing Technology) at room temperature for 2 h, then washed and
incubated with HRP-conjugated anti-rabbit immunoglobulin
(DAKO) at room temperature for 2 h. Immunoreactive protein
bands were identified with Pierce ECL Plus Western Blotting
Substrate (Thermo Fisher Scientific).
Treatment of TGF-b receptor inhibitor. Cells were seeded at a
density of 5 9 105 cells per 100 mm dish with RPMI-1640
containing 10% fetal bovine serum (FBS). The following day,
cells were treated with 1 lM or 10 lM A-83-01 and the med-
ium was changed every 2 days until 7 days post-treatment.
Cells were trypsinized, counted the viable cells, and prepared
for flow cytometry and RT-PCR.
Animal experiments. SIX1-transfectants were transplanted
into scid/scid mice by subcutaneous injection of 5 9 106,
1 9 107, or 2 9 107 cells under anesthesia. Briefly, the cells
were resuspended in a 6:4 mixture of medium and Matrigel
(BD Biosciences). Tumor growth of total six mice was
observed for 7 weeks. All animal studies were approved by
the Animal Experiments Committee at the National Cancer
Center Research Institute.
Statistical analysis. Clinical samples were classified into two
groups for each analysis: samples in which SIX1 expression
was higher than the mean (SIX1 “high”), and lower than the
mean (SIX1 “low”). Each dataset was analyzed separately and
P-values were calculated by log-rank analysis. The accepted
level of significance was P < 0.05.
Results
Expression of SIX1 in esophageal squamous cell carcinomas
(ESCCs). We first investigated SIX1 and PDPN mRNA expres-
sion in eight ESCC cell lines (TE1, TE3, TE5, TE6, TE8,
TE10, T.Tn, and KYSE510) and normal esophageal epithe-
lium that was divided into basal, epibasal, and differentiated
cell layers by laser-captured microdissection. SIX1 mRNA
was detected in ESCC cell lines by 30 cycles of PCR, while
Fig. 1. Selective expression of SIX1 in esophageal
squamous cell carcinoma (ESCC). (a) Semi-
quantitative RT-PCR analyses of SIX1 and PDPN in
eight ESCC cell lines (30 PCR cycles for SIX1 and
PDPN) and three layers (Differentiated, Epibasal,
and Basal cell layer) of normal esophageal mucosa
(50 PCR cycles for SIX1 and 30 PCR cycles for PDPN).
(b) Quantitative RT-PCR of SIX1 in 60 pairs of
primary ESCCs and the matched normal tissues. (c)
Quantitative RT-PCR of SIX1 in 42 ESCC specimens
classified with no lymph node metastasis (N0,
n = 12) and high metastasis (N ≥ 5, n = 30). Data
are mean  SD from three independent
experiments. * P < 0.05. (d) Overall survival of 42
ESCC patients stratified by SIX1 expression level.
P-values are calculated by log-rank test.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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that was detected in normal basal cell layer only by more
than 50 cycles. Accordingly, we concluded that SIX1 was
activated in most of the ESCC cell lines, but suppressed in
normal epithelium (Fig. 1a). Correlation in mRNA expression
between SIX1 and PDPN, which is a basal and ductal cell
marker, was observed in ESCC cell lines except TE10
Fig. 2. Expression of SIX1 in normal esophagus,
hyperplasia, early esophageal squamous cell
carcinoma (ESCC) and advanced ESCC.
Representative images of immunohistochemistry for
SIX1 in normal esophagus (left top), hyperplasia
(right top), early cancer (left bottom), and invasive
front in advanced ESCCs (right bottom). Section is
counterstained with hematoxylin. SC, squamous
cell. Scale bars represent 500 lm and 200 lm.
Fig. 3. SIX1 regulated genes related to epithelial-
mesenchymal transition (EMT) by transforming
growth factor-b (TGF-b) pathway. (a) Semi-
quantitative RT-PCR of SIX1, an epithelial marker
(CDH1), a mesenchymal marker (VIM), TGF-b related
genes (TGFB2 and TGFBI), and their receptors
(TGFBR1and TGFBR2) in TE1 cells transiently
transfected with human SIX1 cDNA or mock vector.
Total RNA is recovered from cells at 48 h after
transfection. A size marker lane is cropped from a
photograph. (b) Matrigel invasion assay of TE3 cells
transiently knockdown by SIX1 siRNA (upper right).
Cells are transferred into matrigel at 24 h after
transfection of SIX1 or control siRNA. Migrated cells
are counted at 24 h after transfer. Data are
mean  SD from three independent experiments.
Data of quantitative RT-PCR (upper left) and
Western blotting (lower) of SIX1 are also shown. (c)
Quantitative RT-PCR analysis of SIX1 in SIX1-stable
transfectants (TE6-SIX1-13 and TE6-SIX1-17) and
mock-transfectants (TE6-Mock). Data are
mean  SD from three independent experiments.
* P < 0.05, *** P < 0.005. (d) Semi-quantitative RT-
PCR of SIX1 and TGF-b signal-related genes (TGFB2,
TGFBI, TGFBR1, TGFBR2, SOX2, and SOX4) in the
two SIX1-transfectants and mock-transfectants.
Lanes of a size marker, positive control (left of TE6-
Mock), and another unstable clone (right) are
cropped from a photograph. Photographs of five
full uncut gels were shown in Fig. S3.
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(Fig. 1a). Next, we analyzed the mRNA expression of SIX1
in 60 pairs of primary ESCCs and its corresponding normal
portions by real-time RT-PCR, and found more than 90% of
ESCCs showed aberrant expression of SIX1 (Fig. 1b, red
lines). We also investigated the relationship between the SIX1
mRNA level and the status of lymph node metastasis in 42
surgically resected specimens of locally advanced ESCC
(stage II and III). The result showed that SIX1 mRNA
expression was significantly higher in 30 cases that had more
than five metastatic lymph nodes than in 12 cases with no
metastatic lymph nodes (Fig. 1c). Accordingly, the high SIX1
expression was significantly correlated with the poor progno-
sis of ESCC patients received by surgery alone (Fig. 1d). We
also performed immunohistochemical analyses to evaluate
SIX1 protein expression in normal mucosa, hyperplasia, and
cancer. Consistent with the above mRNA expression analyses,
SIX1 was expressed neither in normal stratified squamous
cell layer nor hyperplasia, but was expressed in the normal
duct and tumor basal cells of an early ESCC (Fig. 2). Of
particular note, SIX1 was positively stained at basal layers or
the invasive front in advanced ESCCs (Fig. 2), indicating its
involvement in invasion and cell motility. Based on these
results, we focused on the impact of SIX1 expression on
epithelial-mesenchymal transition (EMT) and on tumor basal
cell or cancer stem cell phenotype, since SIX1 has been
reported to be an EMT inducer in breast cancer.(19, 20)
SIX1 induces TGF-b signal-related genes and undifferentiated
basal cell phenotype in ESCC cells. To investigate the biological
role of SIX1 in ESCCs, we performed transient transfection of
SIX1 cDNA to TE1 cells. RT-PCR analysis revealed that over-
expression of SIX1 led to upregulation of a mesenchymal mar-
ker, vimentin (VIM), and downregulation of an epithelial
marker, E-cadherin (CDH1) (Fig. 3a). Interestingly, a series of
the TGF-b related genes (TGFBI and TGFB2) and their recep-
tor genes (TGFBR1 and 2) were highly expressed accompany-
ing SIX1 overexpression (Fig. 3a). Furthermore, the invasive
ability of TE3 cells was significantly reduced by siRNA-based
knockdown of SIX1 mRNA and protein (Fig. 3b). These
results suggest that SIX1 promotes tumor invasion through
EMT induction via TGF-b signaling in ESCC.
Next, we chose TE6 cell line with low invasion ability
(Fig. S1) and established two clones stably expressing SIX1
(TE6-SIX1-13 and TE6-SIX1-17) by limiting dilution
(Fig. 3c). Consistent with transient transfection of SIX1 cDNA
to TE1 with a quit low SIX1 expression (Fig. 3a) and with that
of SIX1 siRNA to TE3 with a significant SIX1 expression
Fig. 4. Continues expression of SIX1 alter
esophageal squamous cell carcinoma (ESCC) cell to
tumor basal phenotype. (a) Semi-quantitative RT-
PCR of SIX1 and normal basal cell or stem cell
markers (NGFR, TP63, PDPN, PTPRZ1, LGR6, and
ALDH1A1) in three layers (differentiated, epibasal,
and basal cell layer) of normal esophageal mucosa.
A size marker lane is cropped from a photograph.
(b) Semi-quantitative RT-PCR of SIX1 and the six
above stem cell markers in two SIX1-transfectants
(TE6-SIX1-13 and TE6-SIX-17) and mock-
transfectants (TE6-Mock). Lanes of a size marker,
positive control (left of TE6-Mock), and another
unstable clone (right) are cropped from a
photograph. Photographs of four full uncut gels
were shown in Fig. S6. (c) Matrigel invasion assay of
SIX1-transfectants. The migrated cells counted at
24 h after transfer into wells. Data are mean  SD
from three independent experiments. * P < 0.05,
** P < 0.01. (d) Flow cytometry analysis of SIX1-
transfectants for PDPN expression. Cells are double-
stained by anti-PDPN antibody and PI. Only viable
cells are analyzed. (e) Immunohistochemical study
of xenografted tumors of TE6-Mock and TE6-SIX1-
17. HE (left), anti SIX1 antibody (middle) anti-PDPN
antibody (right). Scale bars represent 20 lm.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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(Fig. S2), both TE6-SIX1-13 and TE6-SIX1-17 transfectants
highly expressed TGF-b signal-related genes (TGF-b ligands,
their receptors and downstream transcription factors SOXs)
compared to the empty vector-transfected mixed clones, ter-
med TE6-Mock (Fig. 3d). Lanes of a size marker, positive
control (left of TE6-Mock), and another unstable clone (right)
are cropped from a photograph. Photographs of five full uncut
gels were shown in Fig. S3. We also confirmed no difference
in their expression levels between the parental TE6 cell line
and the TE6-Mock (Fig. S4). Since the CDH1 induction and
VIM reduction were shown by transient SIX1 cDNA transfec-
tion (Fig. 3a), it should be noted that the reduction of CDH1
mRNA and the induction of an EMT marker (VIM) and five
EMT regulators (SNAI2, ZEB1, ZEB2, TWIST1, and TWIST2)
by SIX1 were not observed in the two SIX1-transfectants
(Fig. S5). These data suggested that a main role of SIX1 in
ESCC is the induction of TGF-b signal-related genes.
Furthermore, these two cell lines also highly expressed many
markers for undifferentiated esophageal epithelial cells (i.e.
basal and epibasal cells) such as NGFR, SOX2, TP63, PDPN,
PTPRZ1, and LGR6 (Fig. 4a,b). Lanes of a size marker, posi-
tive control (left of TE6-Mock), and another unstable clone
(right) are cropped from a photograph. Photographs of four full
uncut gels were shown in Fig. S6. In accordance with a result
of SIX1 knock down (Fig. 3b), both SIX1-transfectant showed
higher invasive abilities than that of mock-transfectants
(Fig. 4c). To explore the relationship of SIX1 and cancer stem
cells, we selected PDPN from genes selectively-expressed in
undifferentiated esophageal epithelial cells, since it has been
reported that PDPN is a cancer stem cell marker of squamous
cell carcinoma.(21,22) Flow cytometry analysis showed both of
the SIX1-transfectants contained a high PDPN-positive fraction
(66.7% and 59.2%, respectively) compared to that of TE6-
Mock (20.7%) (Fig. 4d). We also assessed the tumorigenicity
of mock- and SIX1-transfectants in immunodeficient mice. As
a result, only the mouse transplanted TE6-SIX1-17 cells,
which stably over-expressed SIX1 by multiple passages, devel-
oped a massive tumor (data not shown). Furthermore,
Fig. 5. Predominant expression of SIX1 in locally
advanced esophageal squamous cell carcinoma
(ESCC) patients with high expression of basal cell
markers. (a) Immunohistochemistry of PDPN and
SIX1 in serial sections obtained from two ESCCs. (b)
Quantitative RT-PCR of SIX1, basal cell markers
(ALDH1A1, PDPN, and SOX2), and differentiated
cell markers (KRT4, FLG, SCEL, and SBSN) in 85
biopsy samples from locally advanced ESCC patients
before definitive CRT. H&I: high (40 cases) and
intermediate (25 cases) in SIX1 mRNA level, L: low
(20 cases) in SIX1 mRNA level. Data are mean  SD
from three independent experiments. * P < 0.05.
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histopathological analysis revealed this tumor tissue to be com-
posed of PDPN-expressed cells and showed poorly differenti-
ated histology (Fig. 4e). These results suggest that SIX1
enhances tumorigenicity and invasiveness and maintains or
increases PDPN-positive cancer stem cells.
Correlation between expression of SIX1 and tumor basal cell
markers in poor prognostic ESCC patients. We investigated colo-
calization of PDPN and SIX1 in tumor basal cells by serial
section. In case A, both SIX1 and PDPN are diffusely stained,
consistent with xenografted tumors of poorly-differentiated
transfectant TE6-SIX1-17 (Figs 4e, 5a). In case B, they are
colocalized at the peripheral zone where the tumor basal cells
existed in the well-differentiated type of ESCCs, consistent
with xenografted tumors of well-differentiated cell line
KYSE510 (Figs 5a and S7). We further examined the correla-
tion between mRNA expression of SIX1 and that of basal cell
markers or differentiated markers from 85 locally advanced
ESCC patients. In the SIX1 high and intermediate cases (40
and 25 cases, respectively), all basal cell markers (PDPN,
ALDH1A1, and SOX2) were highly expressed compared with
the SIX1 low cases (20 cases) (Fig. 5b). In contrast, well-
known differentiation markers of squamous cells (KRT4, FLG,
SCEL, and SBSN) were significantly suppressed in the SIX1
high cases (Fig. 5b). These results also support the notion that
SIX1 promotes cancer stem cell self-renewal and suppresses
differentiation. Although transient transfection of SIX1 cDNA
or siRNA did not alter PDPN expression (data not shown),
these results indicate that SIX1 cannot directly induce PDPN
expression, but can accelerate self-renewal of PDPN-positive
tumor basal cells both in vitro (Fig. 4d) and in vivo (Fig. 4e).
To further investigate the correlation between SIX1 and
PDPN in ESCC patients received by chemoradiotherapy fol-
lowed by surgery, immunohistochemical analyses of some nor-
mal tissues and 85 ESCCs were performed. Although PDPN
mRNA was detected in both the basal and epibasal cell layers
(Figs 1a, 4a), PDPN protein was stained only at the basal cells
in normal esophagus (Fig. 6a). Therefore, the expression of
PDPN is independent from that of SIX1 in the normal epithe-
lium. In primary ESCCs, the PDPN distribution differed
among cases (Fig. 6a). Positive type 1 case was diffusely and
strongly stained by anti-PDPN antibody. In positive type 2
case, PDPN staining was not strong but diffuse. Although the
staining appeared weak in the positive type 3 case because of
abundant stroma, almost all the cancer cells were stained. Posi-
tive types 1, 2, and 3 showed poorly-differentiated histology
and were determined as totally positive, whereas positive type
4 case showed a well-differentiated histology and was stained
only at the periphery of the tumor nest. Notably, PDPN-nega-
tive cases (43/85, 51%) or positive type 4 cases (26/85, 30%)
showed a significantly better prognosis than those with positive
types 1–3 cases (16/85, 19%) (Fig. 6b).
Blockade of TGF-b signaling diminishes PDPN-positive cancer
stem cells. Finally, we tried blocking of TGF-b signaling to
examine whether self-renewal of ESCC cells is dependent on
Fig. 6. PDPN co-localized with SIX1 is a poor
prognostic factor in esophageal squamous cell
carcinoma (ESCC). (a) Representative patterns of
immunohistochemical staining of PDPN in normal
esophagus and primary ESCCs. Section is
counterstained with hematoxylin. (b) Overall
survival of 85 ESCC patients classified by PDPN
staining patterns. P1-3: 16 cases with three positive
staining patterns (positive 1-3), N+P4: 69 cases with
a positive staining pattern, positive 4 (n = 26) or
negative (n = 43). P-values are calculated by log-
rank test.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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this signal pathway. The PDPN-positive cell population in 8
ESCC cell lines (TE1, TE3, TE5, TE6, TE8, TE10, T.Tn, and
KYSE510) was 0.1, 85.3, 24.3, 3.4, 90.2, 1.0, 88.3, and
25.8%, respectively. After exposure to small molecular inhibi-
tor of TGF-b receptor A-83-01(23) for 7 days, the relative via-
bility was significantly decreased in all of the four ESCC cell
lines (TE3, TE8, T.Tn, and KYSE510) harboring a high
PDPN-positive cell population (Fig. 7a). In TE3 and KYSE510
highly sensitive to A-83-01, its PDPN-positive cell population
was significantly reduced by A-83-01(Fig. 7b). Conversely,
TGF-b treatment increased PDPN-positive cell population in
TE3 and KYSE510 (Fig. S8).
The status of PDPN overexpression in two transfectants,
TE6-SIX1-13 and TE6-SIX1-17, was examined by Western
blotting (Fig. S9). Unfortunately, PDPN expression in TE6-
SIX1-13 was decreased by multiple passages for a year. There-
fore, we used only TE6-SIX1-17 in these experiments. We first
showed that the phospho-Smad2/3 level increases more in
TE6-SIX1-17 than in TE6-Mock after TGF-b treatment in a
dose dependent manner, suggesting that TGF-b signal is acti-
vated by SIX1 (Fig. 7c, upper), and also confirmed that the
phosphorylation of Smad2/3 was inhibited by A-83-01
(Fig. 7c, lower). Accordingly, the relative viability was signifi-
cantly low in TE6-SIX1-17 compared with TE6-Mock
(Fig. 7d). PDPN-positive cell population was also reduced in
TE6-SIX1-17 but not in TE6-Mock. Representative FACS data
were shown (Fig. 7e).
Discussion
The Six family of homeodomain transcription factors plays an
important role in early embryogenesis(9) and normal develop-
ment.(10–12) Among this family, SIX1 has been reported to
express aberrantly in various types of tumors including hepato-
cellular carcinoma,(13) cervical cancer,(14) ovarian cancer,(15)
colorectal cancer,(16) and breast cancer.(18) SIX1 has also been
reported as being responsible for tumor progression, invasion
or metastasis in some cancers such as hepatocellular carci-
noma,(24) rhabomyosarcoma,(25) and breast cancer.(18) In infil-
trating ductal breast carcinomas, the aberrant expression of
SIX1 was caused predominantly by gene amplification.(26)
Despite the strong relation between SIX expression and cancer
progression that has been reported, detailed molecular func-
tions of the SIX1 as an oncogene are at the beginning of
understanding. For instance, CCNA1 has been reported to be a
downstream effector of SIX.(27) EZR has been shown to be a
target of SIX1 and to activate several oncogenes.(25) SIX1
inhibits TRAIL-mediated apoptosis in ovarian cancer,(15) and
Fig. 7. Blockade of transforming growth factor-b
(TGF-b) signaling induces cell death and reduces
PDPN-positive cell population. (a, b) Cell viability
and PDPN-positive rate of 4 ESCC cell lines (TE3,
TE8, T.Tn., and KYSE510) with a high PDPN cell
population at 7 days exposure by 10 lM TGF-b
receptor inhibitor (A-83-01). * P < 0.05, ** P < 0.01,
*** P < 0.005. (c) Induction of the phospho-Smad2/3
at 24 h after TGF-b treatment and reduction of the
phospho-Smad2/3 at 48 h after A-83-01 treatment
in the nuclei of TE-Mock and TE6-SIX1-17. (d, e) Cell
viability and PDPN-positive cell population of TE6-
Mock and TE6-SIX1-17 at 7 days exposure by 10 lM
A-83-01. Data are mean  SD from three
independent experiments. * P < 0.05.
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induces EMT through ZEB1 activation and miR200 repression
in colorectal cancer.(16) In breast cancer, Micallizi et al. and
Farabaugh et al. have reported that SIX1 also mediates EMT
and induces cancer stem cell phenotypes through TGF-b sig-
naling.(19,20) Another study has reported that SIX1 switches
TGF-b signaling from tumor suppressive to tumor promoting
by regulating miR106b-25 and Smad7.(28) In ESCC, we found
that SIX1 is also aberrantly expressed (Figs 1b, 2). More sig-
nificantly, the cases with high SIX1 expression showed high
lymph node metastasis and poor survival in surgery alone or
chemoradiotherapy followed by surgery (Figs 1c,d, 6b). These
findings strongly indicate that SIX1 is involved in cancer
malignancy by promotion of metastasis. On the contrary, in
ESCC patients who received definitive CRT, no significant dif-
ference is found, though cases with high SIX1 expression had
a tendency for a worse prognosis (data not shown). This is
partly because the malignant potential cannot be attributed to
only one transcription factor. Many factors are reported to be
associated with EMT in ESCC such as TWIST1,(29) SNAI1,(30)
hedgehog pathway,(31) and FOXA1.(32)
Transient transfection studies of SIX1 cDNA and siRNA
showed that SIX1 induced EMT and invasiveness in ESCC
(Fig. 3a,b), and the stable SIX1-transfectants showed high
invasiveness without EMT (Figs 4c and S5). It should be noted
that the reduction of CDH1 mRNA and the induction of an
EMT marker (VIM) and five EMT regulators by SIX1 were
not observed in the two SIX1-transfectants (Fig. S5). These
data suggested that the role of SIX1 in ESCC is the induction
of TGF-b signal-related genes but is unclear in the authentic
EMT induction.
In accordance with previous findings in breast cancers, SIX1
activated TGF-b (Fig. 3a,d). Furthermore, we investigated
whether SIX1 induces a cancer stem cell phenotype, since
EMT is often accompanied by cancer stem cell properties.(5)
We first found that SIX1 induces some genes selectively
expressed at the normal basal layer where esophageal tissue
stem cells are thought to reside (Fig. 4a,b). Although little is
known about the cancer stem cells of ESCC,(6) PDPN has been
reported to be a cancer stem cell marker of oral squamous cell
carcinoma.(21) In addition, Rahadiani et al. reported PDPN-
positive ESCC cells have a tumor initiating ability.(22) We con-
firmed that PDPN protein expression is selectively expressed
at tumor basal cells of xenografted tumors and primary ESCCs
(Figs 6a and S7). Thus, we used PDPN as a cancer stem cell
marker of ESCC. Both SIX1-overexpressing stable cell lines
(TE6-SIX1-13 and TE6-SIX1-17) had a higher population of
PDPN-positive cells compared to that of TE6-Mock (Fig. 4d).
In addition, PDPN expression was still high in the xenografted
tumor of a SIX1-stably expressing ESCC cell line (Fig. 4e).
Therefore, these studies indicate that consistent SIX1 overex-
pression accelerated self-renewal of PDPN-positive cancer
stem cells and promoted tumor progression. Co-expression
between SIX1 and three basal cell markers (PDPN, ALDH1A1,
and SOX2) and reverse correlation between SIX1 and four dif-
ferentiation markers (KRT4, FLG, SCEL, and SBSN) in biopsy
samples of locally advanced ESCC patients supported this
notion (Fig. 5b).
Although TGF-b signaling induces EMT in various
tumors,(33,34) this mechanism is not well-known in ESCC.
Recently, Natsuizaka et al. reported that immortalized esopha-
geal epithelial cells underwent EMT through TGF-b.(35) Our
data showed that TGFB was upregulated by SIX1 (Fig. 3a,d).
It is reported that the autocrine of TGF-b mediates tumori-
genicity through SOX2/SOX4 in glioblastoma.(36) Likewise,
we found SOX2/SOX4 is upregulated as well as TGFB by
SIX1 transfection (Fig. 3d). In addition, treatment by A-83-01,
a small-molecule inhibitor of the TGF-b receptor, suppressed
growth of SIX1- and PDPN-expressing ESCC cells (Fig. 7d,e).
This result indicates that self-renewal of cancer stem cells of
ESCC promoted by SIX1 is dependent on TGF-b signaling. To
our knowledge, this is the first report that shows the effective-
ness of the TGF-b receptor inhibitor for ESCC. More signifi-
cantly, there is no finding about a specific inhibitor of the
cancer stem cell of ESCC.
In conclusion, our study demonstrated that aberrant expression
of SIX1 is correlated with metastasis and poor survival in ESCC
patients. We also found that SIX1 accelerates self-renewal of
cancer stem cells of ESCCs. This process is dependent on TGF-
b signaling, and TGF-b receptor inhibitors may be effective in
highly malignant ESCC with high SIX1 expression.
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Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article:
Fig. S1. Relative migration ability of eight ESCC cell lines (TE8, TE3, T.Tn, KYSE510, TE1, TE5, TE6, and TE10) and an oral cancer cell line
(A431) assessed by matrigel invasion assay.
Fig. S2. Quantitative RT-PCR of TGF-b signal-related genes (TGFB2, TGFBI, TGFBR1, TGFBR2, SOX2, and SOX4) in TE3 with SIX1 siRNA
treatment. * P < 0.05.
Fig. S3. Photographs of 5 full uncut gels before cropping to make Fig. 3d were shown.
Fig. S4. Expression of SIX1 and TGF-b signal-related genes (TGFB2, TGFBI, TGFBR1, TGFBR2, and TGFBR3) in the parental TE6 cell line
(TE6-Parent) and its mock-transfectants (TE6-Mock).
Fig. S5. Expression of an epithelial cell marker (CDH1), an EMT marker (VIM) and 5 EMT regulators (SNAI2, ZEB1, ZEB2, TWIST1, and
TWIST2) in the three SIX1-transfectants (TE6-Mock, TE6-SIX1-13, and TE6-SIX1-17).
Fig. S6. Photographs of 4 full uncut gels before cropping to make Fig. 4b were shown.
Fig. S7. Representative images of HE staining and immunohistochemistry for PDPN in xenografted tumors of a well-differentiated ESCC cell line,
KYSE510.
Fig. S8. TGF-b treatment increased PDPN-positive cell population in TE3 and KYSE510. * P < 0.05, ** P < 0.01.
Fig. S9. Western blots to evaluate the stability of SIX1 expression in two transfectants after multiple passages. SIX1 (left), ACTB (right).
Table S1. Primer sequences for RT-PCR.
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